Corporate Member Spotlight: Nanose Medical

Nanose Medical's vision is to save lives and reduce the health economic burden by enabling efficient patient management through a point-of-care risk stratification tool. The company is developing a fast, non-invasive, AI-driven breath analysis platform based on a proprietary nanosensor array. Upon exposure of breath samples to our sensors, our technology generates a unique feature space called a “breathprint,” which is used to train AI models to identify risk for disease and help clinicians triage patients within minutes.

Nanose initially focuses on early lung cancer detection and liver fibrosis staging in MASLD — conditions that are often diagnosed too late due to the lack of scalable screening tools. The company has collected thousands of samples across multiple clinical sites, demonstrating strong clinical performance that outperforms current non-invasive tests, including high sensitivity in early-stage lung cancer. Supported by EU, Israel Innovation Authority, and Google grants, and collaborating with Jefferson Health, Nanose is advancing toward broad clinical adoption with a 14-person team, including 5 PhDs.

We are especially excited to build our presence in Philadelphia, including our activity and collaboration with Jefferson Health. We would be very happy to meet with PICC members, healthcare leaders, investors, strategic partners, and others who may be interested in supporting or collaborating with Nanose Medical as we advance our clinical and commercialization activities in the U.S.

Learn more about Nanose Medical here.